Clinical characteristics of patients with coronary atherosclerosis depending on blood fatty acids
V. S. Shramko,
S. V. Morozov,
E. I. Chernyak,
L. V. Shcherbakova,
A. V. Kurguzov,
A. M. Chernyavskyi,
Yu. I. Ragino https://doi.org/10.17802/2306-1278-2020-9-1-15-24
Abstract
Aim. To examine the differences in clinical parameters in patients with coronary atherosclerosis based on fatty acid profile.
Methods.60 men with angiographically verified atherosclerosis of the coronary arteries underwent the analysis of fatty acids followed by coronary endarterectomy. Patients were divided into two groups after histological analysis of the intimamedia fragments. Men without unstable plaques in the coronary arteries were included in Group 1, whereas patients with unstable atherosclerotic plaques were included in Group 2. Blood serum levels of fatty acids were measured by highefficiency gas-liquid chromatography.
Results.The predicted probability value and the predicted group membership in men with coronary atherosclerosis were calculated using the logistic regression. The following clinical patterns in men with unstable atherosclerotic plaques included increased prevalence of myocardial infarction with the event over 10 years ago, severe angina pectoris (III and IV functional class) and chronic heart failure, in comparison with CAD patients without unstable plaques.
Conclusion. Fatty acid profile was associated with altered individual history of coronary atherosclerosis.
About the Authors
V. S. Shramko
The Institute of Internal and Preventive Medicine, the branch of the Federal Publicly Funded Scientific Institution "Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Federal Research Institute"
Russian Federation
Shramko Viktoriya S.-assistant researcher at the Laboratory of Clinical Biochemical and Hormonal Research of Therapeutic Diseases, Research Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences.
Russian Federation
Shramko Viktoriya S.-assistant researcher at the Laboratory of Clinical Biochemical and Hormonal Research of Therapeutic Diseases, Research Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences.
S. V. Morozov
N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry of the Siberian Branch of Russian Academy of Science
Russian Federation
Russian Federation
Morozov Sergey V.- PhD, Head of the Laboratory of Environmental Studies and Chromatographic Analysis, N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry of Siberian Branch of Russian Academy of Sciences.
9, Lavrentiev Av., Novosibirsk, Russian Federation, 630090
E. I. Chernyak
N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry of the Siberian Branch of Russian Academy of Science
Russian Federation
Russian Federation
Chernyak Elena I.- PhD, senior researcher at the Laboratory of Environmental Studies and Chromatographic Analysis, N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry of Siberian Branch of Russian Academy of Sciences.
9, Lavrentiev Av., Novosibirsk, Russian Federation, 630090
L. V. Shcherbakova
The Institute of Internal and Preventive Medicine, the branch of the Federal Publicly Funded Scientific Institution "Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Federal Research Institute"
Russian Federation
Russian Federation
Shcherbakova Liliia V.- senior researcher at the Laboratory of Clinical, Population and Preventive Studies of Therapeutic and Endocrine Diseases, IIPM – Branch of IC&G SB RAS.
175/1, B. Bogatkova St., Novosibirsk, Russian Federation, 630089
A. V. Kurguzov
Meshalkin National Medical Research Center of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Kurguzov Aleksej V.- researcher at the Aorta and Coronary Arteries Surgery Center, Federal State Budgetary Institution “E. Meshalkin National Medical Research Center” of the Ministry of Health of the Russian Federation.
15, Rechkunovskaya St., Novosibirsk, Russian Federation, 630055
A. M. Chernyavskyi
Meshalkin National Medical Research Center of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Chernyavskyi Alexander M.-PhD, Professor, Honored Scientist of the Russian Federation, Director of “E. Meshalkin National Medical Research Center” of the Ministry of Health of the Russian Federation, Head of the Aorta and Coronary Arteries Surgery Center.
15, Rechkunovskaya St., Novosibirsk, Russian Federation, 630055
Yu. I. Ragino
The Institute of Internal and Preventive Medicine, the branch of the Federal Publicly Funded Scientific Institution "Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Federal Research Institute"
Russian Federation
Russian Federation
Ragino Yuliya I.- Corresponding member of RAS, PhD, Professor, Deputy direction for research at IIPM – Branch of IC&G SB RAS.
175/1, B. Bogatkova St., Novosibirsk, Russian Federation, 630089
References
1. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis (Russian recommendations). Cardiovascular therapy and prevention. 2004: 2-2: 3-36 (In Russian).
2. Shalnova S.A., Deev A.D., Oganov R.G. Factors influencing cardiovascular mortality in Russian population. Cardiovascular Therapy and Prevention. 2005; Т. 4(1): 4-9 (In Russian).
3. Thom T., Haase N., Rosamond W., Howard V.J., Rumsfeld J., Manolio T. et al. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006; 113 (6): e85-el51. doi: 10.1161/CIRCULATIONAHA.105.171600.
4. Boitsov S.A., Pogosova N.V. et al. Cardiovascular prevention 2017. National Guidelines. Russian Journal of Cardiology. 2018;(6):7-122. (In Russian) https://doi. org/10.15829/1560-4071-2018-6-7-122.
5. Malay L.N. Statins in the treatment and prevention of cardiovascular diseases: repetition of the past and optimism for the future. Rational Pharmacotherapy in Cardiology. 2010; 10 (5): 513524 (In Russian). doi:10.20996/1819-6446-2014-10-5-513-524.
6. Pogosova N. V., Oganov R. G., Suvorov S. V. Why cardiovascular mortality in Moscow is lower than in other regions of the Russian Federation? Cardiovascular therapy and prevention. 2015; 14(2): 4-12 (In Russian). doi. org/10.15829/1728-8800-2015-2-4-12.
7. Moiseev V. S., Martynov A. I., Mukhin N. A. Internal diseases. Vol.1. 3rd ed. Moscow: GEOTAR-Media; 2015 (In Russian).
8. Bäck M. Omega-3 fatty acids in atherosclerosis and coronary artery disease. Future Sci OA. 2017; 3 (4): FSO236. doi: 10.4155/fsoa-2017-0067.
9. Chen X., Liu L., Palacios G., Gao J., Zhang N., Li G., Lu J., Song T., Zhang Y., Lv H. Plasma metabolomics reveals biomarkers of the atherosclerosis. J Sep Sci. 2010; 33 (17-18): 2776-2783. doi: 10.1002/jssc.201000395.
10. Hamazaki K., Iso H., Eshak E.S., Ikehara S., Ikeda A., Iwasaki M., Hamazaki T., Tsugane S., JPHC Study Group. Plasma levels of n-3 fatty acids and risk of coronary heart disease among Japanese: The Japan Public Health Center-based (JPHC). Atherosclerosis. 2018; 272: 226-232. doi: 10.1016/j. atherosclerosis.2017.12.004.
11. Kleber M.E., Delgado G.E., Dawczynski C., Lorkowski S., März W., von Schacky C. Saturated fatty acids and mortality in patients ref?erred for coronary angiography-The Ludwigshafen Risk and Cardiovascular Health study. J Clin Lipidol. 2018; 12 (2) :455-463.e3. doi: 10.1016/j.jacl.2018.01.007.
12. Zehr K.R., Walker M.K. Omega-3 polyunsaturated fatty acids improve endothelial function in humans at risk for atherosclerosis: A review. Prostaglandins Other Lipid Mediat. 2018; 134: 131-140. doi: 10.1016/j.prostaglandins.2017.07.005.
13. Calder P.C., Deckelbaum R.J. Harmful, harmless or helpful? The n-6 fatty acid debate goes on. Curr Opin Clin Nutr Metab Care. 2011; 14 (2): 113-114. doi: 10.1097/ MCO.0b013e328343d895.
14. Tkacheva N.I., Morozov S.V., Stakhneva E.M., Shramko V.S., Ragino Yu.I. Chromatographic determination of the content of fatty acids in different biological environments at atherosclerotic damages. Atherosclerosis and dyslipidemia. 2017; 1 (26): 17-28 (In Russian).
15. Waksman R., Seruys P.W. Handbook of the Vulnerable Plaque. London; 2004.
16. Cury R.C., Abbara S., Achenbach S., Agatston A., Berman D.S., Budoff M.J., et al. Coronary Artery Disease - Reporting and Data System (CAD-RADS): An Expert Consensus Document of SCCT, ACR and NASCI: Endorsed by the ACC. JACC Cardiovasc Imaging. 2016; 9 (9): 1099-1113. doi: 10.1016/j.jcmg.2016.05.005.
17. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. the task Force for the diagnosis and treatment of acute and chronic heart failure of the european society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Russ J Cardiol. 2017; 1 (141): 7-81 (In Russian). doi: 10.15829/1560-4071-2017-1-7-81.
18. Aronov D.M., Lupanov V.P. Atherosclerosis and coronary heart disease: some aspects of pathogenesis. 2011; 1 (2): 48-56 (In Russian).
19. Falk E., Nakano M., Bentzon J. F., Finn A.V., Virmani R. Update on acute coronary syndromes: the pathologists' view. European Heart Journal. 2013; 34 (10): 719–728. doi: 10.1093/ eurheartj/ehs411.
20. Kochergin N.A., Kochergina A.M., Ganjukov V.I., Barbarash O.L. Vulnerable atherosclerotic plaques of coronary arteries in patients with stable coronary artery disease. Complex Issues of Cardiovascular Diseases. 2018; 7 (3): 65-71. (In Russian). doi: 10.17802/2306-1278-2018-7-3-65-71.
21. Titov V. N., Sazhina N. N., Aripovsky A.V., Evteieva N.M., Tibilova O.A., Kukharchuk V.V. The evaluation of unsaturation of blood lipids using methods of physical chemistry and clinical biochemistry. The insulin regulation of metabolism of fatty acids, number of double binds and cell absorption of glucose. Clinical laboratory diagnostics. 2016; 61(4): 196-204. (In Russian). doi: 10.18821/0869-2084-2016-61-4-196-209.
22. Listenberger L.L., Schaffer J.E. Mechanisms of lipoapoptosis: implications for human heart disease. Trends Cardiovasc Med. 2002; 12 (3): 134-138. doi: 10.1016/ S10501738(02)00152-4.
23. Harvey K.A., Walker C.L., Pavlina T.M., , Xu Z., Zaloga G.P., Siddiqui R.A. Long-chain saturated fatty acids induce proinflammatory responses and impact endothelial cell growth. Clin Nutr. 2010; 29 (4): 492–500. doi: 10.1016/j.clnu.2009.10.008.
24. Kritchevsky D., Tepper S.A., Czarnecki S.K., Sundram K. Red palm oil in experimental atherosclerosis. Asia Pac J Clin Nutr. 2002; 11 Suppl. 7: S433-7. doi: 10.1046/j.1440-6047.11.s.7.5.x.
25. Duarte M.K., de Araújo J.N., Duarte V.H., de Oliveira K.M., de Oliveira J.M., Ferreira Carioca A.A., et al. The relationship of the oleic acid level and ECHDC3 mRNA expression with the extent of coronary lesion. Lipids Health Dis. 2016; 1 (15): 144. DOI: 10.1186/s12944-016-0312-6.
Review
For citations:
Shramko V.S., Morozov S.V., Chernyak E.I., Shcherbakova L.V., Kurguzov A.V., Chernyavskyi A.M., Ragino Yu.I. Clinical characteristics of patients with coronary atherosclerosis depending on blood fatty acids. Complex Issues of Cardiovascular Diseases. 2020;9(1):15-24. (In Russ.) https://doi.org/10.17802/2306-1278-2020-9-1-15-24
Views:
975
